In Cherzan 2023 et al., on subcutaneous mast cell tumors, which characteristic was **not** significantly associated with recurrence, DFI, or survival in dogs with subcutaneous mast cell tumors?
A. Infiltrative pattern
B. Mitotic index >7
C. Lymph node metastasis
D. Multinucleation
E. Local recurrence
Answer: Multinucleation
Explanation: Multinucleation was evaluated but not found to impact prognosis in this study.
In Cherzan 2023 et al., on subcutaneous mast cell tumors, what proportion of dogs with lymph node metastases developed tumor recurrence?
A. 17.8%
B. 26.7%
C. 44%
D. 67%
E. 80%
Answer: 67%
Explanation: 67% (8 of 12) of dogs with LN metastases experienced tumor recurrence.
In Cherzan 2023 et al., on subcutaneous mast cell tumors, what was the median disease-free interval (DFI) for dogs with lymph node metastasis from subcutaneous mast cell tumors?
A. Not reached
B. 551 days
C. 268 days
D. 194 days
E. 139 days
Answer: 194 days
Explanation: Lymph node metastasis significantly reduced DFI to a median of 194 days.
In Cherzan 2023 et al., on subcutaneous mast cell tumors, what impact did incomplete surgical margins (<1 mm) have on recurrence rates of subcutaneous mast cell tumors?
A. They significantly increased recurrence
B. They significantly decreased recurrence
C. They had no significant impact on recurrence
D. They improved DFI
E. They improved survival
Answer: They had no significant impact on recurrence
Explanation: Incomplete margins were not significantly associated with recurrence (*p* = .085).
In Cherzan 2023 et al., on subcutaneous mast cell tumors, which histologic feature was most strongly associated with shorter disease-free interval and survival time?
A. Muscle invasion
B. Infiltrative growth pattern
C. Multinucleation
D. Mitotic index >7
E. Necrosis
Answer: Mitotic index >7
Explanation: Mitotic index >7 was associated with higher recurrence, shorter DFI, and shorter survival.